Market Research

Psychedelic Invest is your source for the latest business and investing news about the burgeoning psychedelics industry.

MindMed CEO, JR Rahn, Pledges Stock For Loan (Not Sale)

Oct 20 • 2 min read

There has been a lot of speculation circulating today after it appeared that the Founder and CEO of Mind Medicine (MMED), JR Rahn, sold half of his shares in the company. A sale by an insider, let alone a founder, of an early stage company is never a good sign as it implies that the…

The Right and Wrong Way To Invest in Psychedelics

Oct 20 • 5 min read

The usage of psychedelic drugs as a therapeutic tool will have an enormous payoff for patients who are seeking new ways to cope with mental health issues. But the advancement of psychedelics is also going to have massive payoffs for early investors in companies that provide these therapies. We are already starting to see a…

New MindMed Warrants Offer An Interesting Buying Opportunity

Oct 11 • 4 min read

Mind Medicine (MMED), one of the leading pharmaceutical companies exploring possible treatment options with psychedelic drugs, has announced a new stock offering. Mind Medicine (or, MindMed) announced that they have entered into an agreement with Canaccord Genuity Corp. for the purchase of 23,810,000 units of the company for C$1.05 per unit. The offering will raise…

Psychedelic Medicine Faces its Next Challenge: Access

Sep 25 • 4 min read

Psychedelic therapies are making rapid inroads on the legal front. Residents of both Washington D.C. and Oregon will vote on decriminalizing psilocybin mushrooms this November and the city council in Ann Arbor, Mich., home to the University of Michigan, this week voted in favor of a resolution to make “investigating or arresting anyone in the…

Compass Pathways: Navigating Mental Health Pathways, all the way to the NASDAQ

Sep 12 • 9 min read

Compass Pathways (CMPS) is going public. If you’ve been watching the field for a few years, it’s hard to say it comes as a surprise. Since its arrival on the scene in 2015, years ahead of its competitors, all signs point to Compass being the largest and most influential company in the psychedelic domain. Aside…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354